ArticleCommunications medicine2026
Peripheral blood mononuclear cell DNA methylation signatures guide surgical decision-making in indeterminate pulmonary nodules.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDistinguishing malignant from benign pulmonary nodules remained a significant clinical challenge. Given the involvement of DNA methylation in anti-tumor immunity, we aimed to investigated whether DNA methylation patterns in peripheral blood mononuclear cells (PBMCs) could serve as non-invasive biomarkers for pulmonary nodule classification.
methodsGenome-wide DNA methylation profiling was performed using Methylome-seq on PBMCs from Discovery cohort, including patients with benign pulmonary nodules (BPN), minimally invasive adenocarcinoma (MIA), and early-stage invasive adenocarcinoma (eIAC). Differential analysis identified 56 candidates differentially methylated cytosines (DMCs) and regions (DMRs). Subsequently, 2 methylation features were validated using targeted bisulfite sequencing (TBS) in the Train cohort and Test cohort. We further developed 2 machine learning models integrating the DNA methylation features and routine blood biomarkers to enhance pulmonary nodule classification accuracy. SurgMalig Model was a surgical malignancy classifier used to differentiate between benign nodules and malignant nodules requiring surgical resection. And ResectGuide Model was a resection guide classifier used to subdivide malignant nodules into MIA and eIAC to inform surgical planning.
resultsThe validated methylation features demonstrate significant discriminatory ability for pulmonary nodules properties compared to conventional blood biomarkers. SurgMalig Model achieves high performance in distinguishing benign from malignant nodules, with area under the curve (AUC) of 0.926 in the Train cohort and 0.806 in the Test cohort. ResectGuide Model effectively classifies MIA and eIAC subtypes, yielding AUC of 0.862 and 0.843 in the respective cohorts.
conclusionsPBMC methylation signatures provide clinically actionable tools for surgical triage in indeterminate pulmonary nodules.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.